NASDAQ:MRKR Marker Therapeutics (MRKR) Stock Price, News & Analysis $5.45 +0.16 (+3.02%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$5.21▼$5.5150-Day Range$3.33▼$5.9652-Week Range$2.40▼$8.85Volume15,691 shsAverage Volume21,081 shsMarket Capitalization$48.61 millionP/E RatioN/ADividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrends Get Marker Therapeutics alerts: Email Address Marker Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside101.8% Upside$11.00 Price TargetShort InterestHealthy1.57% of Float Sold ShortDividend StrengthN/ASustainability-0.75Upright™ Environmental ScoreNews Sentiment0.50Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.64) to ($1.33) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.06 out of 5 starsMedical Sector202nd out of 936 stocksPharmaceutical Preparations Industry84th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingMarker Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageMarker Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Marker Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.57% of the float of Marker Therapeutics has been sold short.Short Interest Ratio / Days to CoverMarker Therapeutics has a short interest ratio ("days to cover") of 4.7.Change versus previous monthShort interest in Marker Therapeutics has recently decreased by 13.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMarker Therapeutics does not currently pay a dividend.Dividend GrowthMarker Therapeutics does not have a long track record of dividend growth. Previous Next 3.9 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMarker Therapeutics has received a 53.36% net impact score from Upright. Marker Therapeutics seems to create the most significant positive value in categories "Jobs", "Creating knowledge", and "Physical diseases". The positive contribution in the "Creating knowledge" impact category is false driven by its "Clinical research services for physical health" and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Marker Therapeutics is -0.75. Previous Next 1.9 News and Social Media Coverage News SentimentMarker Therapeutics has a news sentiment score of 0.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Marker Therapeutics this week, compared to 1 article on an average week. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Marker Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders17.35% of the stock of Marker Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 22.39% of the stock of Marker Therapeutics is held by institutions.Read more about Marker Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Marker Therapeutics are expected to grow in the coming year, from ($1.64) to ($1.33) per share.Price to Book Value per Share RatioMarker Therapeutics has a P/B Ratio of 3.45. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Marker Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable Prosperity“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.You can find out what they are by clicking here now. About Marker Therapeutics Stock (NASDAQ:MRKR)Marker Therapeutics, Inc., a clinical-stage immuno-oncology company, engages in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. Its multi tumor associated antigen-specific T cell technology is based on the manufacture of non-engineered tumor-specific T cells that recognize multiple tumor-associated antigens. The company also develops MT-401-OTS for the treatment of acute myeloid leukemia; and MT-601 to treat lymphoma and pancreatic cancer. Marker Therapeutics, Inc. is headquartered in Houston, Texas.Read More MRKR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart MRKR Stock News HeadlinesJuly 25 at 10:25 AM | finance.yahoo.comITRCC to Begin Pavement Improvements on Indiana Toll Road From Mile Marker 10 to 20 in Lake County, INJuly 19, 2024 | finance.yahoo.comMarker Therapeutics (NASDAQ:MRKR) shareholders are up 20% this past week, but still in the red over the last five yearsJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 28, 2024 | investorplace.comMRKR Stock Earnings: Marker Therapeutics Reported Results for Q4 2023May 26, 2024 | msn.comSpecial bronze DAR 250 Patriots Marker to be dedicated Memorial Day at TPWM CenterMay 16, 2024 | msn.comCombining two tumor markers can help track down colorectal cancer subtypesMay 16, 2024 | investorplace.comMRKR Stock Earnings: Marker Therapeutics Reported Results for Q1 2024May 15, 2024 | globenewswire.comMarker Therapeutics Reports First Quarter 2024 Financial Results and Provides Business UpdatesJuly 26, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 13, 2024 | msn.comReinstalling a Midstate MarkerMay 13, 2024 | msn.comFatal collision occurs on SH 176 at Mile Marker 240 in Andrews CountyMay 2, 2024 | uk.investing.comMarker Therapeutics stock gets Buy from Ladenburg citing CAR-T therapy potentialMay 2, 2024 | benzinga.comMarker Therapeutics Stock (NASDAQ:MRKR), Analyst Ratings, Price Targets, PredictionsMay 1, 2024 | msn.comLadenburg Thalmann Initiates Coverage of Marker Therapeutics (MRKR) with Buy RecommendationApril 30, 2024 | msn.comMile Marker 158 Dockside - Orange Beach, ALApril 27, 2024 | msn.com‘Useful way of marking history’: National Historic Marker Day asks residents to clean off local signsApril 27, 2024 | msn.com'Useful way of marking history': National Historic Marker Day asks residents to clean off local signsApril 10, 2024 | investing.comMarker Therapeutics Inc (MRKR)See More Headlines Receive MRKR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Marker Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/15/2024Today7/26/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRKR CUSIPN/A CIK1094038 Webwww.markertherapeutics.com Phone(713) 400-6400FaxN/AEmployees8Year Founded2018Price Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+104.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$3.31 million Price / Sales14.53 Cash FlowN/A Price / Cash FlowN/A Book Value$1.58 per share Price / Book3.41Miscellaneous Outstanding Shares8,920,000Free Float7,372,000Market Cap$48.08 million OptionableNot Optionable Beta1.53 Social Links 7 Stocks to Own Before the 2024 ElectionLooking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.Get This Free Report Key ExecutivesDr. Juan F. Vera M.D. (Age 44)Co-Founder, CEO, President, Treasurer, Secretary & Director Comp: $399.25kMs. Elizabeth DonnellyDirector of AdministrationDr. Maria-Bernadette Madel (Age 34)Director of Corporate Operations & External Communications Mr. Edmund CheungVice President of Human ResourcesDr. Nadia Agopyan Ph.D.Senior Vice President of Regulatory AffairsDr. Monic Stuart M.D.Chief Medical OfficerPatricia AllisonHead of Clinical OperationsDr. Robert Z. Florkiewicz Sr.Senior Director of Molecular Biology & VirologyMore ExecutivesKey CompetitorsSatsuma PharmaceuticalsNASDAQ:STSAAptorum GroupNASDAQ:APMEyenoviaNASDAQ:EYENClearside BiomedicalNASDAQ:CLSDSeres TherapeuticsNASDAQ:MCRBView All Competitors MRKR Stock Analysis - Frequently Asked Questions How have MRKR shares performed this year? Marker Therapeutics' stock was trading at $5.50 on January 1st, 2024. Since then, MRKR stock has decreased by 0.9% and is now trading at $5.45. View the best growth stocks for 2024 here. How were Marker Therapeutics' earnings last quarter? Marker Therapeutics, Inc. (NASDAQ:MRKR) posted its earnings results on Wednesday, May, 15th. The company reported ($0.27) EPS for the quarter. The firm earned $1.24 million during the quarter. How do I buy shares of Marker Therapeutics? Shares of MRKR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Marker Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Marker Therapeutics investors own include Amarin (AMRN), Viking Therapeutics (VKTX), PhaseBio Pharmaceuticals (PHAS), SCYNEXIS (SCYX), Matinas BioPharma (MTNB), Genocea Biosciences (GNCA) and Strongbridge Biopharma (SBBP). This page (NASDAQ:MRKR) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredCollapse of the PetrodollarThe death of the "petrodollar" seems imminent. And the implications could not be worse for Americans. Ru...Colonial Metals | SponsoredRare signal predicts 50% market drop - before electionThe market is near all-time highs, we're told that unemployment is low, AI's a gift to humanity, and the FED w...Behind the Markets | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored5 Stocks that could triple in a week Robinhood traders have piled $78 billion into this market... Driving tiny tech stock gains of 3,000%, 8,942...Traders Agency | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Marker Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Marker Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
